Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Treasury Shares (2017 - 2025)

Historic Treasury Shares for Denali Therapeutics (DNLI) over the last 9 years, with Q3 2025 value amounting to $5.2 million.

  • Denali Therapeutics' Treasury Shares rose 2961.74% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year increase of 2961.74%. This contributed to the annual value of $4.1 million for FY2024, which is 1357.18% up from last year.
  • According to the latest figures from Q3 2025, Denali Therapeutics' Treasury Shares is $5.2 million, which was up 2961.74% from $5.1 million recorded in Q2 2025.
  • Denali Therapeutics' Treasury Shares' 5-year high stood at $5.2 million during Q3 2025, with a 5-year trough of $2.6 million in Q3 2021.
  • Moreover, its 5-year median value for Treasury Shares was $3.7 million (2023), whereas its average is $3.7 million.
  • In the last 5 years, Denali Therapeutics' Treasury Shares soared by 6478.23% in 2021 and then surged by 742.99% in 2024.
  • Quarter analysis of 5 years shows Denali Therapeutics' Treasury Shares stood at $2.6 million in 2021, then grew by 26.64% to $3.3 million in 2022, then increased by 9.14% to $3.6 million in 2023, then rose by 13.57% to $4.1 million in 2024, then increased by 25.4% to $5.2 million in 2025.
  • Its last three reported values are $5.2 million in Q3 2025, $5.1 million for Q2 2025, and $4.8 million during Q1 2025.